BRAF and carcinoma: These mutations are enriched in carcinoma, with significant enrichment of BRAF V558E in urothelial carcinoma (p = 3.92 × 10−14) and BRAF V695E in pulmonary adenocarcinoma (p = 3.52 × 10−8) (Fig. 6a,b).